查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2129325

全球認知功能數位生物標記市場預測至2034年：按生物標記領域、資料來源、測量方法、臨床階段、最終用戶和地區分類

Cognitive Digital Biomarkers Market Forecasts to 2034 - Global Analysis By Biomarker Domain (Memory, Attention, Language, Executive Function, Motor Cognition and Other Biomarker Domains), Data Source, Measurement, Clinical Stage, End User, and Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球認知功能數位生物標記市場預計將在 2026 年達到 9 億美元，並在預測期內以 18.9% 的複合年成長率成長，到 2034 年達到 36 億美元。

認知功能數位生物標記是指透過數位設備和技術收集的、可客觀測量的用於評估認知、行為或神經功能的資料點。這些生物標記可來自智慧型手機使用情況、穿戴式感測器、語音模式、眼動、運動數據、睡眠模式以及數位認知評估。人工智慧 (AI) 和先進的分析技術能夠將這些訊號轉化為記憶力、注意力、執行功能或其他認知特徵變化的指標。認知功能數位生物標記支援臨床研究、遠端監測、早期評估和個人化醫療保健。數位醫療技術的日益普及正在推動認知功能數位生物標記的發展。

市場動態

認知障礙盛行率不斷上升

阿茲海默症、失智症和輕度認知障礙等認知障礙的日益普遍，使得開發能夠實現早期檢測的客觀認知評估工具變得特別迫切。數位技術的進步使得被動式和連續式監測成為可能，從而拓展了在不同人群中進行生物標記檢測的可能性。藥廠增加對認知障礙治療的研發投入，推動了對生物標記和臨床試驗終點的需求。數位生物標記的法規核准正在促進市場發展和商業化。早期檢測對於有效介入至關重要。

臨床檢驗和法規核准均受到限制。

數位生物標記缺乏足夠的臨床檢驗和法規核准，限制了其在醫療機構和臨床實踐中的應用。高度敏感的認知資料涉及隱私和安全問題，可能影響患者參與和資料共用。不同設備間測量標準化的技術挑戰限制了資料的可比較性和普適性。與臨床工作流程的整合也存在障礙。檢驗要求繁瑣且耗時。

開發用於早期檢測的數位生物標記

用於早期檢測和疾病進展監測的數位生物標記的開發為平台提供者帶來了巨大的成長機會。與遠端醫療和遠距監測平台的整合正在擴大其臨床應用範圍和患者可近性。與製藥公司合作進行臨床試驗正在創造商機並檢驗途徑。人工智慧和機器學習的進步正在提高生物標記的準確性和預測價值。早期檢測在治療結果中的重要性日益凸顯。

與傳統神經心理評估的比較

與傳統神經心理學評估的競爭可能會限制數位生物標記在臨床實踐中的應用。監管方面關於數位生物標記合格的不確定性，對市場開發和商業化構成風險。數位評估的保險報銷額度有限，限制了醫療保健市場的成長。資料安全漏洞可能對信任度和平台採用率產生重大影響。在許多情況下，傳統評估方法仍然是臨床的黃金標準。

新型冠狀病毒（COVID-19）的影響：

新冠疫情加速了人們對遠端評估和監測解決方案的興趣，包括用於臨床試驗的認知功能數位生物標記。臨床試驗的中斷增加了對遠端認知功能評估能力的需求。疫情後時期，人們對數位健康監測的興趣依然濃厚。遠端醫療和數位健康解決方案的日益普及推動了生物標記的應用。遠端監測已成為醫療保健服務中的重要內容。

在預測期內，記憶體領域預計將佔據最大的市場佔有率。

在預測期內，記憶力領域預計將佔據最大的市場佔有率。這是因為記憶力障礙是臨床和研究領域中最廣泛認可和評估的認知領域。記憶力生物標記對於評估和監測阿茲海默症和失智症至關重要。完善的臨床框架為記憶力生物標記的開發和法規核准提供了支持。記憶力仍是認知生物標記研究的重點。

在預測期內，穿戴式裝置產業預計將呈現最高的複合年成長率。

在預測期內，穿戴式裝置領域預計將呈現最高的成長率，這主要得益於消費者對智慧型手錶和健身追蹤器的日益普及，這些裝置能夠被動地監測認知功能。穿戴式裝置可以持續收集與認知相關的活動模式、睡眠和生理指標數據。穿戴式健康監測技術的日益普及正在加速生物標記的開發和商業化。穿戴式裝置提供非侵入式、連續的資料採集功能。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其先進的醫療保健基礎設施、強大的製藥研發能力以及對數位健康技術的早期應用。美國擁有眾多領先的數位生物標記公司和實力雄厚的臨床研究機構。對認知功能研究的大量投入進一步鞏固了該地區的市場領先地位。此外，該地區的數位生物標記法律規範也最為完善。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於醫療保健投資的增加、認知障礙盛行率的上升以及數位醫療的快速普及。認知功能評估能力在中國、日本和印度正在不斷提升。老年人口的成長和醫療保健的現代化正在加速市場成長。全部區域的醫療保健基礎設施建設也持續推進。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管/政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球認知功能數位生物標記市場：按生物標記領域分類

  • 記憶
  • 筆記
  • 語言
  • 執行函數
  • 運動認知
  • 其他

第6章：全球認知功能數位生物標記市場：依資料來源分類

  • 智慧型手機
  • 穿戴式裝置
  • 聲音的
  • 鍵盤
  • 相機
  • 其他

第7章 全球認知功能數位生物標記市場：依測量方法分類

  • 反應時間
  • 言語模式
  • 輸入模式
  • 行人徒步區
  • 表情
  • 其他

第8章：全球認知功能數位生物標記市場：依臨床階段分類

  • 篩檢
  • 診斷
  • 監測
  • 進步
  • 治療反應
  • 其他

第9章：全球認知功能數位生物標記市場：按最終用戶分類

  • 醫院
  • 診所
  • 研究中心
  • 製藥公司
  • 學術機構
  • 其他

第10章 全球認知功能數位生物標記市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟、合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Altoida, Inc.
  • Click Therapeutics, Inc.
  • Neurotrack Technologies, Inc.
  • EarlySense Ltd.
  • Digital Cognition Technologies, Inc.
  • Biogen Inc.
  • Eli Lilly and Company
  • Roche Holding AG
  • Novartis AG
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Signant Health
  • Medidata Solutions, Inc.
  • Clario
  • IXICO plc
Product Code: SMRC39348

According to Stratistics MRC, the Global Cognitive Digital Biomarkers Market is accounted for $0.9 billion in 2026 and is expected to reach $3.6 billion by 2034 growing at a CAGR of 18.9% during the forecast period. Cognitive digital biomarkers are objectively measurable data points collected through digital devices and technologies to evaluate cognitive, behavioral, or neurological functions. These biomarkers can be derived from smartphone interactions, wearable sensors, speech patterns, eye movements, movement data, sleep patterns, and digital cognitive assessments. Artificial intelligence and advanced analytics help transform these signals into indicators of changes in memory, attention, executive function, or other cognitive characteristics. Cognitive digital biomarkers support clinical research, remote monitoring, early assessment, and personalized healthcare. Growing adoption of digital health technologies is driving development of cognitive digital biomarkers.

Market Dynamics

Driver:

Rising prevalence of cognitive disorders

Rising prevalence of cognitive disorders including Alzheimer's disease, dementia, and mild cognitive impairment is creating urgent need for objective cognitive assessment tools that enable early detection. Advances in digital technologies enabling passive, continuous monitoring are expanding biomarker measurement possibilities across diverse populations. Growing pharmaceutical R&D investment in cognitive disorder therapeutics is increasing demand for clinical trial biomarkers and endpoints. Regulatory acceptance of digital biomarkers is supporting market development and commercialization. Early detection is critical for effective intervention.

Restraint:

Limited clinical validation and regulatory approval

Limited clinical validation and regulatory approval for digital biomarkers constrain adoption in healthcare settings and clinical practice. Data privacy and security concerns regarding sensitive cognitive data may affect patient participation and data sharing. Technical challenges in standardizing measurements across diverse devices limit data comparability and generalizability. Integration with clinical workflows presents implementation barriers. Validation requirements are extensive and time-consuming.

Opportunity:

Development of digital biomarkers for early detection

Development of digital biomarkers for early detection and disease progression monitoring presents significant growth opportunities for platform providers. Integration with telehealth and remote monitoring platforms is expanding clinical applications and patient access. Pharmaceutical partnerships for clinical trial use are creating revenue opportunities and validation pathways. Advances in AI and machine learning are improving biomarker accuracy and predictive value. Early detection is becoming increasingly important for treatment outcomes.

Threat:

Competition from traditional neuropsychological assessments

Competition from traditional neuropsychological assessments may limit digital biomarker adoption in clinical settings. Regulatory uncertainties regarding digital biomarker qualification pose risks to market development and commercialization. Limited reimbursement coverage for digital assessments constrains healthcare market growth. Data security breaches could significantly damage trust and platform adoption. Traditional assessments remain the clinical gold standard in many settings.

Covid-19 Impact:

The COVID-19 pandemic accelerated interest in remote assessment and monitoring solutions, including cognitive digital biomarkers for clinical trials. Clinical trial disruptions increased demand for remote cognitive assessment capabilities. The post-pandemic period has witnessed sustained interest in digital health monitoring. Growing acceptance of telemedicine and digital health solutions supports biomarker adoption. Remote monitoring has become a priority for healthcare delivery.

The memory segment is expected to be the largest during the forecast period

The memory segment is expected to account for the largest market share during the forecast period as memory impairment represents the most recognized and measured cognitive domain in clinical and research settings. Memory biomarkers are essential for Alzheimer's disease and dementia assessment and monitoring. Established clinical frameworks support memory biomarker development and regulatory acceptance. Memory remains the primary focus of cognitive biomarker research.

The wearables segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the wearables segment is predicted to witness the highest growth rate driven by increasing consumer adoption of smartwatches and fitness trackers enabling passive cognitive monitoring. Wearable devices can continuously collect data on activity patterns, sleep, and physiological markers relevant to cognition. Growing acceptance of wearable health monitoring is accelerating biomarker development and commercialization. Wearables offer non-intrusive continuous data collection capabilities.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to advanced healthcare infrastructure, strong pharmaceutical R&D presence, and early adoption of digital health technologies. The United States hosts leading digital biomarker companies and clinical research organizations with established capabilities. Significant funding for cognitive research reinforces regional market leadership. Regulatory pathways for digital biomarkers are most advanced in the region.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by growing healthcare investment, increasing prevalence of cognitive disorders, and rapid digital health adoption. China, Japan, and India are expanding cognitive assessment capabilities. Rising elderly populations and healthcare modernization are accelerating market growth. Healthcare infrastructure development continues across the region.

Key players in the market

Some of the key players in the Cognitive Digital Biomarkers Market include Altoida, Inc., Click Therapeutics, Inc., Neurotrack Technologies, Inc., EarlySense Ltd., Digital Cognition Technologies, Inc., Biogen Inc., Eli Lilly and Company, Roche Holding AG, Novartis AG, Pfizer Inc., Merck & Co., Inc., Signant Health, Medidata Solutions, Inc., Clario, and IXICO plc.

Key Developments:

In May 2025, Altoida, Inc. launched an enhanced cognitive digital biomarker platform for Alzheimer's disease detection and monitoring. The platform leverages smartphone-based assessments and AI analytics to provide objective cognitive measures. The launch responds to growing demand from pharmaceutical companies for clinical trial biomarkers.

In March 2025, Neurotrack Technologies, Inc. announced significant enhancements to its digital cognitive assessment platform with new biomarkers for memory and executive function monitoring. The enhancements strengthen the platform's clinical utility and research applications.

Biomarker Domains Covered:

  • Memory
  • Attention
  • Language
  • Executive Function
  • Motor Cognition
  • Other Biomarker Domains

Data Sources Covered:

  • Smartphones
  • Wearables
  • Voice
  • Keyboards
  • Cameras
  • Other Data Sources

Measurements Covered:

  • Reaction Time
  • Speech Patterns
  • Typing Patterns
  • Gait
  • Facial Behavior
  • Other Measurements

Clinical Stages Covered:

  • Screening
  • Diagnosis
  • Monitoring
  • Progression
  • Treatment Response
  • Other Clinical Stages

End Users Covered:

  • Hospitals
  • Clinics
  • Research Centers
  • Pharmaceutical Companies
  • Academic Institutions
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Cognitive Digital Biomarkers Market, By Biomarker Domain

  • 5.1 Memory
  • 5.2 Attention
  • 5.3 Language
  • 5.4 Executive Function
  • 5.5 Motor Cognition
  • 5.6 Other Biomarker Domains

6 Global Cognitive Digital Biomarkers Market, By Data Source

  • 6.1 Smartphones
  • 6.2 Wearables
  • 6.3 Voice
  • 6.4 Keyboards
  • 6.5 Cameras
  • 6.6 Other Data Sources

7 Global Cognitive Digital Biomarkers Market, By Measurement

  • 7.1 Reaction Time
  • 7.2 Speech Patterns
  • 7.3 Typing Patterns
  • 7.4 Gait
  • 7.5 Facial Behavior
  • 7.6 Other Measurements

8 Global Cognitive Digital Biomarkers Market, By Clinical Stage

  • 8.1 Screening
  • 8.2 Diagnosis
  • 8.3 Monitoring
  • 8.4 Progression
  • 8.5 Treatment Response
  • 8.6 Other Clinical Stages

9 Global Cognitive Digital Biomarkers Market, By End User

  • 9.1 Hospitals
  • 9.2 Clinics
  • 9.3 Research Centers
  • 9.4 Pharmaceutical Companies
  • 9.5 Academic Institutions
  • 9.6 Other End Users

10 Global Cognitive Digital Biomarkers Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Altoida, Inc.
  • 13.2 Click Therapeutics, Inc.
  • 13.3 Neurotrack Technologies, Inc.
  • 13.4 EarlySense Ltd.
  • 13.5 Digital Cognition Technologies, Inc.
  • 13.6 Biogen Inc.
  • 13.7 Eli Lilly and Company
  • 13.8 Roche Holding AG
  • 13.9 Novartis AG
  • 13.10 Pfizer Inc.
  • 13.11 Merck & Co., Inc.
  • 13.12 Signant Health
  • 13.13 Medidata Solutions, Inc.
  • 13.14 Clario
  • 13.15 IXICO plc

List of Tables

  • Table 1 Global Cognitive Digital Biomarkers Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Cognitive Digital Biomarkers Market, By Biomarker Domain (2023-2034) ($MN)
  • Table 3 Global Cognitive Digital Biomarkers Market, By Memory (2023-2034) ($MN)
  • Table 4 Global Cognitive Digital Biomarkers Market, By Attention (2023-2034) ($MN)
  • Table 5 Global Cognitive Digital Biomarkers Market, By Language (2023-2034) ($MN)
  • Table 6 Global Cognitive Digital Biomarkers Market, By Executive Function (2023-2034) ($MN)
  • Table 7 Global Cognitive Digital Biomarkers Market, By Motor Cognition (2023-2034) ($MN)
  • Table 8 Global Cognitive Digital Biomarkers Market, By Other Biomarker Domains (2023-2034) ($MN)
  • Table 9 Global Cognitive Digital Biomarkers Market, By Data Source (2023-2034) ($MN)
  • Table 10 Global Cognitive Digital Biomarkers Market, By Smartphones (2023-2034) ($MN)
  • Table 11 Global Cognitive Digital Biomarkers Market, By Wearables (2023-2034) ($MN)
  • Table 12 Global Cognitive Digital Biomarkers Market, By Voice (2023-2034) ($MN)
  • Table 13 Global Cognitive Digital Biomarkers Market, By Keyboards (2023-2034) ($MN)
  • Table 14 Global Cognitive Digital Biomarkers Market, By Cameras (2023-2034) ($MN)
  • Table 15 Global Cognitive Digital Biomarkers Market, By Other Data Sources (2023-2034) ($MN)
  • Table 16 Global Cognitive Digital Biomarkers Market, By Measurement (2023-2034) ($MN)
  • Table 17 Global Cognitive Digital Biomarkers Market, By Reaction Time (2023-2034) ($MN)
  • Table 18 Global Cognitive Digital Biomarkers Market, By Speech Patterns (2023-2034) ($MN)
  • Table 19 Global Cognitive Digital Biomarkers Market, By Typing Patterns (2023-2034) ($MN)
  • Table 20 Global Cognitive Digital Biomarkers Market, By Gait (2023-2034) ($MN)
  • Table 21 Global Cognitive Digital Biomarkers Market, By Facial Behavior (2023-2034) ($MN)
  • Table 22 Global Cognitive Digital Biomarkers Market, By Other Measurements (2023-2034) ($MN)
  • Table 23 Global Cognitive Digital Biomarkers Market, By Clinical Stage (2023-2034) ($MN)
  • Table 24 Global Cognitive Digital Biomarkers Market, By Screening (2023-2034) ($MN)
  • Table 25 Global Cognitive Digital Biomarkers Market, By Diagnosis (2023-2034) ($MN)
  • Table 26 Global Cognitive Digital Biomarkers Market, By Monitoring (2023-2034) ($MN)
  • Table 27 Global Cognitive Digital Biomarkers Market, By Progression (2023-2034) ($MN)
  • Table 28 Global Cognitive Digital Biomarkers Market, By Treatment Response (2023-2034) ($MN)
  • Table 29 Global Cognitive Digital Biomarkers Market, By Other Clinical Stages (2023-2034) ($MN)
  • Table 30 Global Cognitive Digital Biomarkers Market, By End User (2023-2034) ($MN)
  • Table 31 Global Cognitive Digital Biomarkers Market, By Hospitals (2023-2034) ($MN)
  • Table 32 Global Cognitive Digital Biomarkers Market, By Clinics (2023-2034) ($MN)
  • Table 33 Global Cognitive Digital Biomarkers Market, By Research Centers (2023-2034) ($MN)
  • Table 34 Global Cognitive Digital Biomarkers Market, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 35 Global Cognitive Digital Biomarkers Market, By Academic Institutions (2023-2034) ($MN)
  • Table 36 Global Cognitive Digital Biomarkers Market, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.